<DOC>
	<DOCNO>NCT01334905</DOCNO>
	<brief_summary>The purpose study evaluate safety YM178 effect food intake pharmacokinetics YM178 healthy adult subject .</brief_summary>
	<brief_title>A Study Investigate Safety Effect Food Pharmacokinetics YM178 Healthy Volunteers</brief_title>
	<detailed_description>A open-label , randomize , crossover study assess effect food pharmacokinetics single dose YM178 administer fasted fed condition .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>A normal clinically nonsignificant 12 lead ECG well normal clinically nonsignificant laboratory test result time Screening Body weigh least 50 kg male 45 kg female body mass index ( BMI ) 18.5 26.9 kg/m2 All woman child bear potential require use adequate contraception consist two form birth control Hypersensitivity YM178 beta3 agonists constituent formulation use Liver function test value upper limit normal A history presence psychiatric illness , serious active recurrent infection A previous history cancer basal cell carcinoma Stage 1 squamous cell carcinoma remission least 5 year prior study Donated lose â‰¥ 500 mL blood within 3 month donate plasma within 2 week prior study Receiving anticipate receive prescription drug OTC medication within 14 day prior study Consuming alcohol , xanthine derivativecontaining food/beverages ( tea , chocolate ) , grapefruit juice , grapefruitcontaining product Seville orange ( e.g. , bitter marmalade ) within 48 hour study A history substance abuse , drug addiction , alcoholism within past 2 year prior study currently participate another clinical trial take take investigational drug least 60 day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>YM178</keyword>
	<keyword>mirabegron</keyword>
	<keyword>Food effect</keyword>
</DOC>